-
Retrotope Expands its Drug Pipeline with the First Dosing of RT001 in Patients with FA
The Friedreich’s Ataxia Research Alliance (FARA) shared the following:
Jennifer Farmer, Chief Executive Officer, (FARA) commented, “We are excited to see RT001 advance to a phase 2/3 efficacy study, and we are actively working to assist in patient recruitment efforts to ensure the study enrolls efficiently and meets its enrollment goals. FARA has been committed to creating and sharing the research community resources such as patient registries, natural history data, and validated clinical outcome measures along with fostering patient engagement in research in order to assist Retrotope and other drug development partners in advancing clinical development programs.”
Click the link to read the full press release bit.ly/2FC6pMZ
How do you feel about these news? What do you think this means for the FA Community?
-
1 Reply
-
That sounds wonderful! What will it do? Is it supposed to stop progression or do something else?
Log in to reply.